Praxis Precision Medicines, INC 8-K filings

Praxis Precision Medicines reports positive topline results from its EMBOLD study, showing a significant reduction in seizures and improved outcomes for patients with SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) using relutrigine.

Praxis Precision Medicines announced its Q2 2024 financial results and provided a corporate update, highlighting progress across its clinical programs and a strong cash position.

Praxis Precision Medicines' stockholders approved an amendment to their 2020 Stock Option and Incentive Plan, increasing the available shares, and elected two Class I directors at their 2024 Annual Meeting.

Praxis Precision Medicines announced its first quarter 2024 financial results, highlighted by progress in clinical trials and a strengthened cash position.

Praxis Precision Medicines has entered into an underwriting agreement for a public offering of common stock and pre-funded warrants, expected to generate approximately $215.6 million in net proceeds.

Praxis Precision Medicines reports successful Phase 2a trial results for PRAX-628, showing a 100% response rate in epilepsy patients with photo paroxysmal response.

Praxis Precision Medicines announced positive clinical trial updates for multiple drug candidates and secured funding to extend operations into 2026.

Praxis Precision Medicines has entered into an underwriting agreement for a public offering of common stock and pre-funded warrants, expected to close on January 16, 2024, with net proceeds estimated at $161.7 million.

Praxis Precision Medicines has terminated its $75 million open market sales agreement with Jefferies, having sold approximately $9.6 million worth of shares under the agreement.